27th week of 2022 patent applcation highlights part 23 |
Patent application number | Title | Published |
20220213169 | METHODS AND COMPOSITIONS FOR INHIBITING ADAM8 BIOLOGICAL ACTIVITIES - This disclosure provides ADAM8 modulating peptides, nucleic acids encoding ADAM8 modulating peptides, and methods for using the same to modulate ADAM8 biological activities in vitro and/or in vivo, to inhibit ADAM8 biological activities associated with diseases or disorders in subjects including gene therapy or cell based therapies. Specifically, methods are provided to decrease inflammation, and to inhibit undesirable cellular proliferation, fibrosis, and angiogenesis. In some embodiments, the ADAM8 modulating peptides or nucleic acids encoding them include modifications of one or more amino acids of the human ADAM8 prodomain amino acid sequence, and in some embodiments the ADAM8 modulating peptides include other modifications such as but not limited to the addition of PEG groups. | 2022-07-07 |
20220213170 | PEPTIDES - There is disclosed a peptide comprising a fragment of SEQ ID NO: 2 or SEQ ID NO: 8. The fragment comprises at least 8 consecutive amino acids of SEQ ID NO: 8, including at least one of positions 121 and 135 of SEQ ID NO: 8. Alternatively, the fragment comprises positions 6 to 13 of SEQ ID NO: 3 and the peptide comprises no more than 21 amino acids, the fragment comprises positions 7 to 22 of SEQ ID NO: 3 and the peptide comprises no more than 40 amino acids, or the fragment comprises positions 18 to 33 of SEQ ID NO: 3, and the peptide comprises no more than 33 amino acids. Alternatively, the fragment comprises the amino acid sequence of SEQ ID NO: 29, and the peptide comprises no more than 21 amino acids and is for use in the treatment and/or prophylaxis of cancer. The peptide is capable of inducing an immune response against a TGFβR2 −1a frameshift mutant protein | 2022-07-07 |
20220213171 | Ciliary Neurotrophic Factor Receptor Ligand-Binding Agents and Methods of Using the Same - Provided are agents that specifically bind a ligand of ciliary neurotrophic factor receptor (CNTFR). In certain aspects, an agent of the present disclosure is a soluble CNTFR polypeptide. The soluble CNTFR polypeptide may have an altered (e.g., reduced) binding affinity for one or more ligand-CNTFR complex subunits, an altered (e.g., increased) binding affinity for one or more CNTFR ligands, or any combination thereof. Compositions that include the agents of the present disclosure are also provided, as are methods of using the agents (e.g., for treating a cell proliferative disorder) and methods of identifying an individual as having a cell proliferative disorder associated with CNTFR signaling. | 2022-07-07 |
20220213172 | VIRAL VECTORS ENCODING RECOMBINANT FVIII VARIANTS WITH INCREASED EXPRESSION FOR GENE THERAPY OF HEMOPHILIA A - The present disclosure provides, among other aspects, codon-altered polynucleotides encoding Factor VIII variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia A. | 2022-07-07 |
20220213173 | MODIFIED COLLAGEN - The present invention relates to a modified collagen obtainable by providing isolated collagen; freezing the isolated collagen; dehydrating the frozen collagen; and maturing the dehydrated collagen. Also disclosed are methods of preparing the modified collagen and uses thereof. | 2022-07-07 |
20220213174 | IVIG TREATMENTS FOR SUDDEN SONSORINEURAL HEARING LOSS - The present invention provides, among other aspects, methods and compositions for treating Hearing Loss, including Sudden Sensorineural Healing Loss in a subject in need thereof, the method comprising: administering a therapeutically effective amount of a composition comprising human intravenous immunoglobulin (IVIG) to a subject. The present invention also provides, methods and composition for treating Hearing Loss, including Sudden Sensorineural Healing Loss in a subject in need thereof, the method comprising: administering a therapeutically effective amount of a composition comprising human IVIG and a steroid. In certain aspects of the present invention the steroid is a cortical steroid, including prednisone or methylprednisone. | 2022-07-07 |
20220213175 | CORONAVIRUS: EARLY DETECTION AND TREATMENT - The application relates to certain new epitope peptides associated with coronavirus envolop protein and the use thereof. In particular, the application describes the antibodies and vaccines developed against these peptides, and the use thereof for the detection and treatment of coronaviral infection in human subjects. | 2022-07-07 |
20220213176 | ANTIBODIES AGAINST SARS-COV-2 SPIKE PROTEIN - The present disclosure provides human antibodies and fragments thereof having binding specificity to the SARS-CoV-2 spike protein's receptor binding domain (RBD). The antibodies and fragments have strong affinity and potent neutralization ability against the SARS-CoV-2 virus and various mutant forms. Also provided are trimeric antibodies which have further enhanced neutralization capabilities. The antibodies and fragments thus may be used for preventing or treating SARS-CoV-2 viral infection or detecting the presence of the virus in a sample. | 2022-07-07 |
20220213177 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME - The present invention relates to immunogenic compositions comprising RSV F protein, methods for preparing compositions that contain RSV F protein ecto-domain polypeptides, and to certain engineered RSV F proteins and nucleic acids that encode the engineered RSV F proteins. Compositions prepared using the methods can contain RSV F protein ecto-domain polypeptides in a predominant or single desired form and conformation. The invention also relates to methods for inducing an immune response to RSV F. | 2022-07-07 |
20220213178 | Enhanced Transfection - The invention relates to a method of transfecting a cell with a molecule, the method comprising the steps of: adding a molecule for transfection to the cells; and modulating the activity of protein kinase C (PKC) in the cell and/or providing a pH responsive peptide comprising between about 5 and about 20 histidine residues; and related compositions and uses in therapy. | 2022-07-07 |
20220213179 | HUMANIZED ANTI-COMPLEMENT FACTOR BB ANTIBODIES AND USES THEREOF - Provided herein are humanized anti-factor Bb antibodies, methods of producing the antibodies and methods of using the antibodies. | 2022-07-07 |
20220213180 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT OF INFECTIOUS DISEASES OR INFLAMMATORY DISEASES - [Problem] To provide a therapeutic method specialized for an inflammatory disease such as intractable vasculitis and an infectious disease, which is different from the previous therapeutic methods, in which a target molecule was not determined, by determining the target molecule useful for treating these diseases. | 2022-07-07 |
20220213181 | ANGIOPOIETIN-LIKE 4 ANTIBODIES AND METHODS OF USE - The present invention relates to monoclonal antibodies binding to human angiopoietin-like 4 protein (hereinafter, sometimes referred to as “ANGPTL4”), and pharmaceutical compositions and methods of treatment comprising the same. | 2022-07-07 |
20220213182 | ANTI-BAG3 ANTIBODIES AS THERAPEUTIC REAGENT IN CARDIOVASCULAR DISEASE - The present invention relates to the use of anti-BAG3 antibodies and its pharmaceutical formulation in the treatment of cardiovascular diseases. | 2022-07-07 |
20220213183 | IL-17A/F HETEROLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF - The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases. | 2022-07-07 |
20220213184 | IL-17A/F HETEROLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF - The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases. | 2022-07-07 |
20220213185 | EPITOPE SPECIFIC TO SMO PROTEIN, ANTIBODY RECOGNIZING SAME, AND COMPOSITION COMPRISING SAME - The present invention identifies the influence of the TGFβ/Smad3/SMO molecular mechanism in cancer cells and elucidates that a high expression level of SMO is associated with the overall survival rate of cancer patients, demonstrating that SMO is a potential prognostic marker for cancer. The present invention relates to a specific epitope of SMO as an antigen and an antibody or a fragment thereof recognizing and binding specifically to the epitope. Therefore, the antibody of the present invention is expected to be useful as a therapeutic agent for SMO-related cancers. | 2022-07-07 |
20220213186 | COMPOSITION FOR PREVENTING OR TREATING BRAIN AND NERVOUS SYSTEM DISEASE - The present invention relates to a composition for preventing, ameliorating, or treating a brain and nervous system disease by using a binding molecule capable of specifically binding to Lrig-1 protein which is a protein present on the surface of regulatory T cells. | 2022-07-07 |
20220213187 | COMPOSITIONS AND METHODS RELATED TO XCT ANTIBODIES - Certain embodiments are directed to therapeutic compositions having an xCT specific antibody. | 2022-07-07 |
20220213188 | METHODS OF TREATING NEURODEGENERATIVE DISEASES - Provided herein is a method for treating neurodegenerative diseases, such as Alzheimer's disease (AD), by use of monoclonal antibody, which exhibits a binding affinity to Siglec-3 receptor. According to some embodiments of the present disclosure, the monoclonal antibody is capable of enhancing phagocytosis of neurotoxic peptides by immune cells thereby providing a neuroprotective effect to a subject in need thereof. | 2022-07-07 |
20220213189 | ANTI-CEACAM6 ANTIBODIES AND METHODS OF USE - The present invention relates to an antigen-binding protein, or an antigen-binding fragment thereof which binding to CEACAM6, comprising (i) a heavy chain variable domain comprising a VHCDR1 having the amino acid sequence GNTFTSYVMH; a VHCDR2 having the amino acid sequence YINPYNDGTKYNEKFKG; and a VHCDR3 having the amino acid sequence STARATPYFYAMDY and (ii) a light chain variable domain comprising a VLCDR1 having the amino acid sequence KSSQSLLWSVNQNSYLS, a VLCDR2 having the amino acid sequence GASIRES, and a VLCDR3 having the amino acid sequence QHNHGSFLPYT. The present invention also relates to compositions comprising the antigen-binding protein, or antigen-binding fragment thereof, methods of use of the antigen-binding protein, or antigen-binding fragment thereof for cancer treatment, prevention or detection and a kit comprising the antigen-binding protein, or antigen-binding fragment thereof. | 2022-07-07 |
20220213190 | ANTI-CD19 ANTIBODY FORMULATIONS - The present disclosure describes a pharmaceutical formulation of an anti-CD19 antibody. | 2022-07-07 |
20220213191 | METHODS OF TREATING UROTHELIAL CARCINOMA USING AN ANTI-PD-1 ANTIBODY - This disclosure provides a method for treating a subject afflicted with a urothelial carcinoma or cancer derived therefrom, which method comprises administering to the subject an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity or the combination of (a) an antibody or an antigen-binding portion thereof that specifically binds to a PD-1 receptor and inhibits PD-1 activity; and (b) an antibody or an antigen-binding portion thereof that specifically binds to a Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) and inhibits CTLA-4 activity. | 2022-07-07 |
20220213192 | BISPECIFIC ANTIBODIES AGAINST PD-1 AND LAG-3 - Bispecific antibodies comprising a first targeting moiety which specifically binds to PD-1 and a second targeting moiety which specifically binds to LAG-3, wherein the first targeting moiety comprises a first VHH domain and the second targeting moiety comprises a second VHH domain. Amino acid sequences of the antibodies of the invention, cloning or expression vectors, host cells and methods for expressing or isolating the antibodies. Therapeutic compositions comprising the antibodies of the invention are also provided and methods for treating cancers and other diseases with the bispecific antibodies. | 2022-07-07 |
20220213193 | BISPECIFIC ANTIBODIES AGAINST CHI3L1 AND PD1 WITH ENHANCED T CELL-MEDIATED CYTOTOXIC EFFECTS ON TUMOR CELLS - Described herein are bispecific antibodies simultaneously targeting both CHI3L1 and the immune checkpoint molecule PD-1. These antibodies manifest enhanced synergistic cytotoxic effects compared to the effects of individual CHI3L1 and PD-1 antibodies, alone or in combination. Methods of treating a cancer by administering the bispecific antibodies described herein are also provided. | 2022-07-07 |
20220213194 | CANCER TREATMENT - The invention provides methods or compositions for treating cancer using a superantigen conjugate optionally in combination with a PD-1-based inhibitor. | 2022-07-07 |
20220213195 | BIFUNCTIONAL FUSION PROTEIN AGAINST PDL1 AND TGF AND USE THEREOF - Provided are an anti-PDL1 antibody and an antigen-binding fragment thereof, and further provided are a bifunctional fusion protein against PDL1 and TGFβ and a preparation method thereof and the use thereof. The antibody or antigen-binding fragment or the bifunctional fusion protein has one or more of the following advantages: an enhanced TGFβ1 binding activity, an enhanced affinity to PDL1, an enhanced ability to block the binding of PDL1 and PD1, an enhanced functional activity for blocking TGFβ1, an enhanced ability to promote the secretion of IFN-γ by T cells, a better immunomodulatory effect and a better tumor inhibitory effect. | 2022-07-07 |
20220213196 | ANTIGEN-BINDING PROTEINS TARGETING SHARED ANTIGENS - Provided herein are HLA-PEPTIDE targets and antigen binding proteins that bind HLA-PEPTIDE targets. Also disclosed are methods for identifying the HLA-PEPTIDE targets as well as identifying one or more antigen binding proteins that bind a given HLA-PEPTIDE target. | 2022-07-07 |
20220213197 | MEDICAMENT AND METHOD FOR TREATING INFECTIOUS DISEASES - This invention relates to the field of medicine, particularly to a medicament for treating bacterial infections, which presents a technology-processed product resulting from multiple serial dilutions of the stock substances of antibodies to HLA-DRB1 and antibodies to β2-microglobulin, and to a combination of the claimed medicament with antibiotic, to a method of treating bacterial infections, a method of reducing bacterial resistance to antibiotic therapy and a method of enhancing antibiotic efficacy. Besides, this invention relates to a medicament for treating infectious diseases, which exerts antibacterial and antiviral effects and presents a technology-processed product resulting from multiple serial dilutions of the stock substances of a) antibodies to HLA-DRB1, b) antibodies to β2-MG, c) antibodies to IFN-γ and d) antibodies to CD4. This invention ensures an effective treatment of infectious diseases, decreases resistance to antibiotics, enhances the therapeutic efficacy of antibiotics, including efficacy against resistant bacteria, and reduces effective doses of antibiotics. | 2022-07-07 |
20220213198 | METHOD OF TREATMENT - The present disclosure relates to methods for the treatment of cancer, methods of increasing the response of tumor cells in a subject to cancer therapy, as well as methods of predicting a positive clinical response to a cancer therapy in a patient. | 2022-07-07 |
20220213199 | Anti-HLA-G antibodies and use thereof - The present invention relates antibodies that bind to human HLA-G, multispecific antibodies thereof, their preparation, formulations and methods of using the same. | 2022-07-07 |
20220213200 | ANTI-GPIIB/IIIA ANTIBODIES OR USES THEREOF - The present invention provides antibodies and antigen-binding molecules thereof which specifically bind the α and/or β subunits of the non-active form of the GPIIb/IIIIa receptor. The antibodies and antigen-binding molecules can be genetically fused and/or conjugated to heterologous moieties and used, for example, as targeting moieties. The invention also includes methods for screening for these antibodies, as well as methods of making and methods of using chimeric molecules derived from the antibodies. | 2022-07-07 |
20220213201 | ANTI-TIE2 ANTIBODY AND USE THEREOF - The present invention relates to an antibody, which specifically binds to tyrosine-protein kinase receptor TIE-2 (TIE2) so as to possess functions of blood vessel normalization and stabilization through receptor phosphorylation, and relates to: an anti-TIE2 antibody; a nucleic acid encoding same; a vector comprising the nucleic acid; a cell transformed with the vector; a method for preparing the antibody; an agent for stabilizing blood vessels and a composition for treating angiogenesis-associated diseases, both of which comprise the antibody; and a composition for co-administration with a pharmaceutical composition for tumor or cancer treatment and with a composition other than an antibody binding to TIE2. | 2022-07-07 |
20220213202 | MULTIFUNCTIONAL NATURAL KILLER (NK) CELL ENGAGERS BINDING TO NKp46 AND CD123 - The present disclosure relates to multifunctional binding proteins comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein the first ABD binds specifically to human CD123 and the second ABD binds specifically to human NKp46 and wherein all or part of the immunoglobulin Fc region or variant thereof to a human Fc-γ receptor. | 2022-07-07 |
20220213203 | Dosing Regimens of Bispecific CD123 x CD3 Diabodies in the Treatment of Hematologic Malignancies - The present invention is directed to a dosing regimen for administering a CD 123×CDS bispecific diabody to patients with a hematologic malignancy such as acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The present invention is also directed to a dosing regimen for administering a CD 123×CDS bispecific diabody in combination with a molecule capable of binding PD-1 or a natural ligand of PD-1 (a “PD-1 or PD-1 ligand binding molecule”) to patients with a hematologic malignancy such as acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The invention particularly concerns the use of such regimens for administering the sequence-optimized CD 123×CDS bispecific diabody, “DART-A,” which is capable of simultaneous binding to CD 123 and CDS. | 2022-07-07 |
20220213204 | CD25-SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND THEIR USES - The present invention relates to proteins which comprise (i) a CD25-specific binding domain, (ii) a linker domain, connecting domain (i) and domain (iii), (iii) a transmembrane domain, and (iv) a signalling domain. The present invention furthermore relates to nucleic acids encoding the proteins, expression constructs for expressing the protein in a host cell and host cells. The present invention further relates to pharmaceutical compositions comprising said protein(s), nucleic acid(s), expression construct(s) or host cell(s). The proteins of the invention are CD25-specific chimeric antigen receptors that are suitable for generating CD25-specific immune cells, which can be used e.g. in the treatment of inflammation. | 2022-07-07 |
20220213205 | MULLERIAN INHIBITING SUBSTANCE TYPE 2 RECEPTOR (MISIIR)-SPECIFIC CAR T CELLS FOR THE TREATMENT OF OVARIAN CANCER AND OTHER GYNECOLOGIC MALIGNANCIES - The present disclosure provides modified immune cells or precursors thereof (e.g., modified T cells) comprising a chimeric antigen receptor (CAR) having affinity for Mullerian inhibiting substance type 2 receptor (MISIIR). Compositions and methods of treatment of ovarian and other gynecologic cancers are also provided. | 2022-07-07 |
20220213206 | COMPOSITIONS AND METHODS FOR AUGMENTING ANTIBODY MEDIATED RECEPTOR SIGNALING - The present invention provides compositions and methods for augmenting antibody mediate receptor signaling. | 2022-07-07 |
20220213207 | IMMUNOMODULATORY ANTIBODIES - The invention relates to antibodies specific for 4-1BB and OX40, as well as to methods for using such antibodies and therapeutic uses thereof. | 2022-07-07 |
20220213208 | ANTI-BCMA ANTIBODIES - This invention provides antibodies that recognize the B Cell Maturation Antigen (BCMA) and that bind naïve B cells, plasma cells, and/or memory B cells. The invention further provides methods for depleting naïve B cells, plasma cells, and memory B cells, and for treating B cell-related disorders, including lymphomas and autoimmune diseases. | 2022-07-07 |
20220213209 | MONOCLONAL ANTIBODY THAT BINDS SPECIFICALLY TO GITR - The present invention relates to biotechnology, in particular to antibodies or antigen-binding fragments thereof, and to use thereof. More particularly, the present invention relates to monoclonal antibodies that specifically bind to GITR. The invention also relates to a nucleic acid encoding said antibody or antigen-binding fragment thereof, an expression vector, a method for preparing said antibody, and use of said antibody in treatment of diseases or disorders associated with GITR. | 2022-07-07 |
20220213210 | COMBINATION THERAPY OF MULTIPLE SCLEROSIS COMPRISING A CD20 LIGAND - The present invention relates to the use of a CD20 ligand and at least one further active agent in the treatment of multiple sclerosis, to the use of a pharmaceutical composition and to a kit comprising the CD20 ligand and at least one further active agent or a pharmaceutical composition comprising such CD20 ligand and further active ingredient. | 2022-07-07 |
20220213211 | ANTIGEN RECOGNIZING RECEPTORS TARGETING CD371 AND USES THEREOF - The presently disclosed subject matter provides for antigen-recognizing receptors that specifically target CD371 and cells comprising such CD371-targeted antigen-recognizing receptors. The presently disclosed subject matter further provides uses of the CD371-targeted antigen-recognizing receptors for treatment. | 2022-07-07 |
20220213212 | METHODS AND COMPOSITIONS FOR TREATING CANCER - Provided herein are methods and compositions for treating cancer or a tumor in a subject by administering to the subject a first agent that disrupts the interaction between PD-L2/RGMb and a second agent that disrupts the interaction between PD-1/PD-L1. The subject may have dysbiosis and/or be nonresponsive to immune checkpoint therapy. | 2022-07-07 |
20220213213 | NOVEL BISPECIFIC POLYPEPTIDES AGAINST CD137 - The invention provides bispecific polypeptides comprising a first binding domain, designated B1, which is capable of binding specifically to CD137, and a second binding domain, designated B2, which is capable of specifically binding to a tumour cell-associated antigen. Also provided are pharmaceutical compositions of such bispecific polypeptides and uses of the same in medicine. | 2022-07-07 |
20220213214 | Anti-human ephrin B1 antibodies and uses thereof - Disclosed herein are isolated anti-human ephrin B1 antibodies, or fragments thereof, and methods for their use in treating tumors. | 2022-07-07 |
20220213215 | POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING GLYPICAN-3 AND T CELL RECEPTOR - The present technology aims at providing a novel type of drug for treating a subject suffering from cancer. Specifically, the technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that one ISVD binds to TCR and at least two ISVDs bind to GPC3. The present technology also provides nucleic acids, vectors and compositions. | 2022-07-07 |
20220213216 | BISPECIFIC ANTIBODY WITH DOUBLE HER2 SITES FOR TUMOR IMMUNOTHERAPY - Disclosed is a bispecific antibody with dual Her2 binding sites, comprising (a) an anti-CD3 antigen-binding fragment Fab, having a light chain variable region VL, a light chain constant region CL, a heavy chain variable region VH and a heavy chain constant region CH1; (b) an anti-Her2 single domain antigen-binding fragment VHH1, linked to the C-terminus of the CL of the Fab and can bind to a first Her2 epitope; and (c) an anti-Her2 single domain antigen-binding fragment VHH2, linked to the C-terminus of CH1 of the Fab and can bind to a second Her2 epitope; the first Her2 epitope and the second Her2 epitope are non-overlapping epitopes of Her2. The bispecific antibody has a killing effect on Her2 tumors with an IHC score of +1, and is effective on trastuzumab-resistant tumors. | 2022-07-07 |
20220213217 | ANTIBODY SUBSTITUTING FOR FUNCTION OF BLOOD COAGULATION FACTOR VIII - The present inventors produced a variety of bispecific antibodies that specifically bind to both F. IX/F. IXa and F. X, and functionally substitute for F. VIIIa, i.e., have a cofactor function to promote F. X activation via F. IXa. Among these antibodies, the antibody A44/B26 reduced coagulation time by 50 seconds or more as compared to that observed when the antibody was not added. The present inventors produced a commonly shared L chain antibody from this antibody using L chains of A44, and showed that A44L can be used as commonly shared L chains, although the activity of the resulting antibody is reduced compared to the original antibody (A44HL-B26HL). Further, with appropriate CDR shuffling, the present inventors successfully produced highly active multispecific antibodies that functionally substitute for coagulation factor VIII. | 2022-07-07 |
20220213218 | BISPECIFIC ANTIBODIES - The invention relates to a bispecific antibody comprising a first antigen-binding site capable of binding Factor VII(a) and a second antigen-binding site capable of binding TLT-1, pharmaceutical formulations comprising such bispecific antibodies and uses thereof. | 2022-07-07 |
20220213219 | Bruton's Tyrosine Kinase as Anti-Cancer Drug Target - Receptor protein kinases (RPTKs) transmit extracellular signals across the plasma membrane to cytosolic proteins, stimulating formation of complexes that regulate key cellular functions. Over 5 half of the known tyrosine kinases are implicated in human cancers and are therefore highly promising drug targets. A large-scale loss-of-function analysis of tyrosine kinases using RNA interference in the clinically relevant Erb-B2 positive, BT474 breast cancer cell line showed that Bruton's tyrosine kinase (BTK), a cytosolic, non-receptor tyrosine kinase that has been extensively studied for its role in B cell development, is required, in altered form, for BT474 10 breast cancer survival. This alternative form contains an amino-terminal extension that is also present in tumorigenic breast cells at significantly higher levels than in normal breast cells. | 2022-07-07 |
20220213220 | ANTI-TYROSINASE ANTIBODY FOR INHIBITING TYROSINASE AND USE THEREOF - The present invention relates to an anti-tyrosinase antibody for inhibiting tyrosinase and use thereof, and more particularly, to an anti-tyrosinase antibody including a heavy chain CDR and a light chain CDR of specific sequences, or an antigen-binding fragment thereof. The anti-tyrosinase antibody is expected to be effectively utilized for improving skin whitening or treating skin pigmentation disorders by inhibiting tyrosinase activity. | 2022-07-07 |
20220213221 | ANTI-RHO GTPASE CONFORMATIONAL SINGLE DOMAIN ANTIBODIES AND USES THEREOF - Active forms of specific anti Rho GTPase conformational single domain antibodies are useful in the therapeutic and diagnostic fields. In particular, single domain antibodies wherein the amino acid sequences of CDR1-IMGT, CDR2-IMGT and CDR3-IMGT have at least 90% of identity with the amino acid sequences of the CDR1-IMGT, CDR2-IMGT and CDR3-IMGT of the H12, B6, 4P75, 4SP1, 4SNP36, 4SNP61, 5SP10, 5SP11, 5SP58, 5SNP47, 5SNP48, 5SNP65, B20, B15, B5, B71, E3, A6, G12, NB61, 212B, 111B or 404F (hs2dAb) are defined in Table B. | 2022-07-07 |
20220213222 | PREVENTION AND TREATMENT OF TYPE-1 DIABETES USING AGONISTS OF THE (NA++K+)-ATPASE - Methods of preventing and treating type-1 diabetes and its complications using peptide vaccines to generate endogenous specific antibody activators that bind to the (Na | 2022-07-07 |
20220213223 | Treatment of Al Amyloidosis with the Combination of Monoclonal Antibodies Agains Immunoglobulin Light Chains and the CD38 Cell Membrane Molecule on Antibody-Producing And Other Immune Cells - Treatment of AL Amyloidosis with the Combination of Monoclonal Antibodies against immunoglobulin Light Chains and Aggregates of Immunoglobulin Light Chains and the CD38 Cell Membrane Molecule on Antibody-Producing and Other Immune Cells. | 2022-07-07 |
20220213224 | T CELL ACTIVATING BISPECIFIC ANTIGEN BINDING MOLECULES - The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells comprising a common light chain. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease. | 2022-07-07 |
20220213225 | MULTISPECIFIC TREG BINDING MOLECULES - Multispecific Treg-binding molecules, constructs, pharmaceutical compositions comprising the constructs, and methods of use thereof are presented. | 2022-07-07 |
20220213226 | ANTI-TL1A/ANTI-TNF-ALPHA BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF - The present invention concerns antigen binding proteins that bind TL1A, including bispecific antigen binding proteins (e.g., antibodies) to TL1A and TNF-α. Such bispecific antibodies can be in a tetrameric immunoglobulin format, in which one heavy chain-light chain pair of the antibody is directed to TL1A and the other to TNF-α. The bispecific antigen binding proteins may also be comprised in an IgG-scFv fusion, in which a conventional tetrameric antibody directed to one antigen is fused to a pair of single chain Fv units directed to the other. The bispecific antigen binding protein may also be comprised in an IgG-Fab fusion, in which a Fab molecule that binds to one antigen is fused to each heavy chain of a conventional tetrameric antibody directed to the other antigen. The invention further relates to uses of the anti-TL1A binding proteins and anti-TL1A/anti-TNF-α antigen binding proteins, and pharmaceutical formulations thereof. | 2022-07-07 |
20220213227 | T CELL RETARGETING HETERO-DIMERIC IMMUNOGLOBULINS - The present invention describes novel hetero-dimeric immunoglobulins or fragments thereof which bind to CD3 and a disease associated antigen. These hetero-dimeric immunoglobulins have been engineered to promote hetero-dimer formation during expression and can be purified to a high degree using a Protein A differential purification technique. | 2022-07-07 |
20220213228 | SCALABLE PRODUCTION OF PROCESSABLE DRIED NANOMATERIALS AND SUPERHYDROPHOBIC SURFACES FROM CELLULOSE NANOMATERIALS - The present disclosure generally relates to a process for manufacturing a processable dried cellulose nanomaterial using a co-solvent of tert-butyl alcohol (TBA), of which unique physical/chemical properties enable facile modification/derivatization. This present disclosure also relates to materials and process of generating of superhydrophobic surface coating using hydrophobic carboxylic acid modified cellulose nanofibers. Both the processes and the products thereof are within the scope of this disclosure. | 2022-07-07 |
20220213229 | METHOD FOR PRODUCING MODIFIED CELLULOSE - The present invention is a method for producing a modified cellulose including the following step A: step A: introducing a cellulose raw material with a substituent having 6 or more carbon atoms to a group in which a hydrogen atom is removed from a hydroxyl group of a cellulose backbone, in the presence of water and a surfactant. The present invention relates to a method for producing a modified cellulose having a high affinity of an organic solvent, a resin or the like, and a hydrophobic medium, using a reaction system with low environmental loads and with prospects of reduction in production costs. | 2022-07-07 |
20220213230 | METHOD FOR PREPARING A HEAT-MODIFIED STARCH - A method for producing a heat-modified starch, comprising the steps of: (i) preparing a starch milk having a solids content of between 20% and 45% by weight and adding an alkaline agent, so as to obtain a final conductivity of between 4 and 7 mS/cm (ii) filtering the starch milk so as to recover a starch cake; (iii) introducing the starch cake, continuously, into a dryer at the same time as a continuous stream of hot air in order to recover a dried powder; (iv) continuously supplying a turboreactor with the dried powder, and by setting parameters for the speed of rotation of the stirrer, so that the dried powder is continuously centrifuged and conveyed into the turboreactor; (v) recovering the heat-modified starch produced. | 2022-07-07 |
20220213231 | MODIFIER, COMPOSITION FOR MODIFICATION CONTAINING THE MODIFIER, FOOD OR BEVERAGE, PHARMACEUTICAL PRODUCT, COSMETIC PRODUCT, INDUSTRIAL PRODUCT, FEED, MEDIUM, OR FERTILIZER USING THE SAME, AND METHOD FOR MODIFYING THESE PRODUCTS - Provided is a novel application of a starch decomposition product. The present technology provides a modifier that includes a starch decomposition product in which the content with a glucose polymerization degree (DP) of 8 to 19 is 32% or more, and the content with a glucose polymerization degree (DP) of 20 or more is 30% or less, and is configured to partially or completely crystallize the starch decomposition product together with raw materials of a target product, thereby modifying qualities of the target product. The modifier used in the present technology can modify qualities of a target product, such as humidity resistance, solidifying properties, gelling properties, shape retainability, plasticity, whiteness, water separation resistance, oil separation resistance, mouthfeel, tactile sensation, aftertaste, creaming properties, heat resistance, thickening properties, and aging resistance. | 2022-07-07 |
20220213232 | BIOHYBRID PEPTIDOGLYCAN OLIGOMERS - The invention relates to a compound of formula Ia and/or formula Ib: or a pharmaceutically acceptable salt, solvate or prodrug thereof, where the groups are defined herein. The invention also relates to a pharmaceutical formulation comprising the compound for treating or detecting a microbial infection in a subject, a method of determining antimicrobial resistance of a microbial infection using the compound, and a method of determining an effective dose of one or more antimicrobial agents to kill a microorganism using the compound. | 2022-07-07 |
20220213233 | CROSSLINKED POLYMER OF FUNCTIONALIZED HYALURONIC ACID AND ITS USE IN THE TREATMENT OF INFLAMMATORY STATES - A crosslinked polymer of functionalized hyaluronic acid, or derivative thereof, is disclosed, as well as a process for its preparation and its use as a biomaterial and as an ingredient in pharmaceutical compositions. The use of this crosslinked polymer in the treatment of disorders ascribable to altered galectin expression, is also disclosed. | 2022-07-07 |
20220213234 | RECYCLABLE CROSS-LINKED DIENE ELASTOMERS COMPRISING FURANYL GROUPS AND PRECURSORS THEREOF - The present invention concerns new precursors of recyclable cross-linked diene elastomers comprising at least one furanyl group along the chain and comprising chain-end units with furanyl groups, their use in the preparation of said recyclable elastomers and their process of preparation. The invention also concerns new recyclable cross-linked diene elastomers, their preparation process and their uses. | 2022-07-07 |
20220213235 | SULFUR-MODIFIED CHLOROPRENE RUBBER AND METHOD FOR PRODUCING SAME, SULFUR-MODIFIED CHLOROPRENE RUBBER COMPOSITION, VULCANIZATE, AND MOLDED ARTICLE - A sulfur-modified chloroprene rubber having a functional group A represented by specific General Formula (A) and positioned at a molecular terminal and a functional group B represented by specific General Formula (B) and positioned at a molecular terminal, in which a mass ratio B/A of a content of the functional group B with respect to a content of the functional group A is more than 0 and 6.00 or less, and a total amount of the functional group A and the functional group B is 0.10 to 0.60% by mass. | 2022-07-07 |
20220213236 | Modified Conjugated Diene-Based Polymer and Rubber Composition Including the Same - A modified conjugated diene-based polymer and a rubber composition including the same are disclosed herein. The modified conjugated diene-based polymer has excellent processability and good tensile strength and viscoelasticity. In some embodiments, a modified conjugated diene-based polymer includes a derived unit from a modifier, the modifier including three or more alkoxy groups bonded to silicon, a non-functional chain forming a silicon-carbon bond at one side of the derived unit from a modifier and including a repeating unit derived from a conjugated diene-based monomer, and a functional chain forming a silicon-carbon bond at the other side of the derived unit from a modifier and including two or more derived units from an N-functional group-containing monomer, wherein the rate of change of mooney viscosity is 20% or less. | 2022-07-07 |
20220213237 | STYRENIC POLYMERS HAVING REDUCED TRIMER CONTENT - Disclosed are styrenic polymers made by a mass or solution process, where the amount of trimer consisting of styrene and/or acrylonitrile is less than about 0.50 weight percent. Also disclosed is a method of minimizing the amount of trimer consisting of styrene and/or acrylonitrile in styrenic polymers made by a mass or solution process. The method includes the steps of lowering the temperature of the polymerization reaction mixture and including more than one initiator in the polymerization reaction mixture. | 2022-07-07 |
20220213238 | RESIN COMPOSITION AND RESIN SHEET - Provided is a resin composition having excellent heat resistance and flame retardance doubled as superior formability. The present invention provides a resin composition comprising: a propylene-based resin and/or an ethylene-based resin; a NOR-type HALS compound represented by formula (1) or formula (2); and a phosphorus compound having a flash point of 360° C. or higher, wherein R is a group represented by formula (2-1). | 2022-07-07 |
20220213239 | Method For Preparing Modification Initiator And Apparatus For Preparing The Same - The present invention relates to a method for preparing a modification initiator, the method capable of reducing side reactions to the minimum and obtaining the modification initiator with a high conversion rate, and an apparatus for performing the same, wherein the method includes (S1) reacting a first fluid including a modification functional group-containing compound and a conjugated diene-based monomer and a second fluid including a polymerization initiation functional group-containing compound, and (S2) obtaining a third fluid including a modification initiator prepared by the reaction of Step S1, wherein the modification functional group-containing compound is used in a ratio of greater than 1 mole based on 1 mole of the polymerization initiation functional group-containing compound, the conjugated diene-based monomer is used in a ratio of 1 mole to 4 moles based on 1 mole of the modification functional group-containing compound, and Step S1 and Step S2 are continuously performed. | 2022-07-07 |
20220213240 | MULTI-COMPONENT COPOLYMER, RUBBER COMPOSITION, RESIN COMPOSITION, TIRE, AND RESIN PRODUCT - An object of the present disclosure is to provide a polymer exhibiting reduced heat generation in a low strain region. To achieve the object, the present disclosure provides a multi-component copolymer, comprising a non-conjugated olefin unit, a conjugated diene unit, and an aromatic vinyl unit, characterized in that: a ratio [(C | 2022-07-07 |
20220213241 | Polyolefin-Based Ionomers and Production Thereof - This invention relates to a process to produce an ionomer comprising: 1) contacting, in a reactor, one or more C | 2022-07-07 |
20220213242 | WAX DISPERSANT AND THERMOPLASTIC RESIN COMPOSITION - An object is to provide a wax dispersant capable of improving the resin composition in the fluidity in a molten state, the transparency and the storage stability, when adding the wax to a thermoplastic resin. The wax dispersant is a copolymer (A) which has a copolymerization composition comprising structural units respectively derived from: an aromatic monomer (A1) within 40 to 94% by mass; a (meth)acrylic acid long chain alkyl ester (A2) represented by the formula (1) (an alcohol residue R | 2022-07-07 |
20220213243 | Polymer, Resist Composition, Method for Manufacturing Substrate Having Pattern Formed Therein, and (Meth)Acrylic Ester and Production Method Therefor - Provided is a polymer including a constituent unit (1) based on a monomer represented by Formula (1), in which a content of a constituent unit based on a monomer having a polycyclic structure is 35 mol % or less. In Formula (1), R | 2022-07-07 |
20220213244 | NOVEL DEMULSIFIER - Disclosed is a novel demulsifier, which is prepared by a method comprising the following steps of: dissolving a fatty alcohol polyether in a solvent to formulate a fatty alcohol polyether solution with a certain concentration; adding an organic catalyst and an olefin acid to the fatty alcohol polyether solution to carry out an esterification reaction for a certain period of time at a certain temperature and rotating speed; after the completion of the esterification reaction, adding an initiator to carry out a polymerization reaction for a certain period of time at a certain temperature and rotating speed; and after the completion of the polymerization reaction, evaporating the solvent in the reaction vessel with a rotary evaporator, and then placing the same in a vacuum drying oven and drying for a certain period of time to obtain the novel demulsifier. | 2022-07-07 |
20220213245 | LIGHT-CURABLE COMPOSITIONS USEFUL FOR FORMING COMPOSITE MATERIALS - Composite materials are formed by photo curing compositions containing one or more cyanoacrylates, substantial amounts of one or more fillers (in particular, opaque and/or fibrous fillers such as carbon fibers) as well as particular photoinitiator systems. The photoinitiator system may comprise, for example, a metallocene compound such as a ferrocene in combination with an acylgermane or other photocleavable compound which generates an acyl radical when exposed to light. Complete, deep curing of such compositions to provide composite materials having improved mechanical properties can be achieved, even though the light used to initiate curing may not be capable of penetrating the entire thickness of the composition due to the presence of the filler. | 2022-07-07 |
20220213246 | PROCESS OF POLYMERIZING TRI-FUNCTIONAL LONG-CHAIN BRANCHED OLEFIN - Processes of synthesizing long-chain branched polymers. The processes include contacting together one or more C | 2022-07-07 |
20220213247 | METHOD FOR PRODUCING DIENE-BASED GRAFT COPOLYMER RESIN AND DIENE-BASED GRAFT COPOLYMER RESIN - Disclosed is a method for producing a diene-based graft copolymer resin, and a diene-based graft copolymer resin produced therefrom, the method including: adding, into a reactor, a polymerization solution containing a diene-based rubber polymer, an aromatic vinyl-based monomer, a vinyl cyan-based monomer, a polymerization initiator, and a reaction solvent, and polymerizing the polymerization solution to prepare a polymer; recovering a solution containing unreacted monomers and a reaction solvent from the polymerization solution, dispersing a releasing agent in the recovered solution, and then adding the solution into the front end of a volatilization tank; and removing the unreacted monomers and the reaction solvent from the volatilization tank. | 2022-07-07 |
20220213248 | RESIN MATERIAL AND METHOD FOR PRODUCING THE SAME - According to the present invention, A resin material including a phenolic resin and a dicyandiamide polymer finely dispersed in the phenolic resin; and a method for producing a resin material including a phenolic resin and a dicyandiamide polymer dispersed in the phenolic resin, the method including a step of preparing a resin composition including the phenolic resin and dicyandiamide and a step of heating the resin composition to polymerize the dicyandiamide and form the dicyandiamide polymer are provided. | 2022-07-07 |
20220213249 | TWO-PART INTERFACE MATERIALS, SYSTEMS INCLUDING THE INTERFACE MATERIAL, AND METHODS THEREOF - The teachings herein relate to new compositions for thermal interface materials that provide improved thermal conductivity without requiring filler materials that are expensive or abrasive. The improved thermal conductivity is achieved using a combination of increased filler loading, selection of a filler having abroad particle size distribution, and selection of filler that is non-abrasive. The thermal interface material preferably has a specific gravity of about 4.0 or less, about 3.0 or less, about 2.5 or less, or about 2.4 or less. The thermal interface material may be a two-part composition. In order to achieve maximum thermal conductivity, each part preferably includes a liquid matrix material and dispersed filler. Upon mixing, the first and second parts may react to increase this viscosity (e.g., by polymerizing and/or cross-linking). The first part preferably includes a carbamate-containing compound that reacts with a carbamate-reactive compound, which is preferably in the second component. The first part preferably is substantially or entirely free of isocyanate containing compounds, as these compounds may reduce the shelf life stability of the composition. The carbamate-reactive compound preferably is a polyamine, including two or more spaced apart amine groups. The first part, the second part, or both, preferably includes a catalyst for accelerating the reaction between the carbamate-containing compound and the carbamate-reactive compound. | 2022-07-07 |
20220213250 | STORAGE STABLE HFO- OR HCFO-CONTAINING POLYOL COMPOSITIONS FOR MAKING FLAME-RESISTANT RIGID POLYURETHANE FOAMS - Formulated polyol compositions include a non-halogenated polyol, a halogenated polyol, a phosphorus-containing flame retardant, an HFO and/or HCFO blowing agent and certain urethane catalysts. The compositions exhibit excellent storage stability. Foams made from the formulated polyol compositions have unexpectedly improved fire performance, as indicated by certain fire tests. | 2022-07-07 |
20220213251 | METHOD FOR SURFACE FUNCTIONALIZATION IN A SUPERCRITICAL FLUID MEDIUM - A method for functionalizing the surface of a substrate, performed in a supercritical fluid medium, may include: (i) providing a substrate having labile hydrogen functions on the surface; (ii) bringing the substrate into contact, in a supercritical fluid, with at least one organic molecule carrying at least one blocked isocyanate function which can be activated by heating; and (iii) subjecting the whole to a temperature sufficient to bring about the release of the blocked isocyanate function carried by the molecule, and the covalent grafting of the molecule by reaction of the isocyanate function with a labile hydrogen function on the surface of the substrate. | 2022-07-07 |
20220213252 | URETHANE-CROSSLINKED BIODEGRADABLE ELASTOMERS - Among other things, the present disclosure provides compositions and methods for an elastomeric cross-linked polyester material. Such an elastomeric cross-linked polyester material, in some embodiments, comprises a plurality of polymeric units of the general formula (-A-B-) | 2022-07-07 |
20220213253 | YELLOWING-RESISTANT THERMOPLASTIC POLYURETHANE FOAM MATERIAL AND PREPARATION METHOD THEREOF - A yellowing-resistant thermoplastic polyurethane (TPU) foam material and a preparation method thereof are provided. The yellowing-resistant TPU foam material includes a TPU prepared by subjecting an aliphatic diisocyanate, a chain extender, a polyol, an antioxidant, an ultraviolet (UV) absorber, and a UV light stabilizer to a reaction, where the TPU has a softening point of 90° C. to 160° C., a Shore hardness of 40 A to 98 A, and a melt index of 5 to 250 g/10 min. The prepared yellowing-resistant TPU foam material has excellent yellowing resistance, controllable foaming density, and uniform foam cell size. | 2022-07-07 |
20220213254 | MASS FIXABLE BY ACTINIC RADIATION, AND USE OF SAID MASS - The invention relates to isocyanate-based, storage-stable, one-part compositions that are fixable by irradiation with actinic radiation and curable by heat. The composition comprises (A) an at least bifunctional, solid isocyanate having a passivated surface and a melting point of at least 40° C.; (B) an isocyanate-reactive component selected from the group of alcohols, amines and thiols, and mixtures thereof; (C) a radiation-curable compound; and (D) a photoinitiator. Optionally, further additives (E) can be contained in the composition according to the present invention. The compositions, by fixation with actinic radiation, can be transferred into a state that ensures dimensional stability of the compositions during heat curing. | 2022-07-07 |
20220213255 | AMINE-INITIATED POLYOLS AS NON-EMISSIVE CATALYSTS IN HR FOAM - A process for producing an amine-based polyol by reacting a tertiary amine with various epoxides in two or more steps. The present disclosure also relates to the amine-based polyol obtained by this process and the use of the amine-based polyol in the production of polyurethanes, wherein the polyurethanes are preferably synthesized based on toluene diisocyanate (TDI) and are preferably molded foams. | 2022-07-07 |
20220213256 | POLYMERIZABLE COMPOSITION FOR OPTICAL MATERIALS AND USE THEREOF - A polymerizable composition for optical materials of the present invention contains (A) a polyisocyanate compound, (B) a polythiol compound, (C) a photochromic compound, (D) a polyether compound having a number-average molecular weight of 50 to 10,000, and (E) a polyether-modified siloxane compound having a viscosity of 1 mPa·s or more and less than 1,600 mPa·s. | 2022-07-07 |
20220213257 | Molecularly Resilient And High-Energy Transferrable Composite Materials And Methods Of Reinforcing Substrates With The Same - A molecularly resilient and high-energy transferable material and method of reinforcing and strengthening substrates with the same. The material includes aliphatic polyurea moieties coated on the surface of a pre-curing or curing epoxy, that may or may not compose a fiber reinforced epoxy (F/E) layer, constituting an isophorone diisocyanate amine (IDA) epoxy-surface modification (reaction) to form an interfacial epoxy-polyurea hybridized-matrix (IEPM) material between the epoxy (that may reside on an F/E layer) and a cured polyurea layer. Through its unique set of molecular vibrational properties, which are designed into the IEPM by controlling the thermodynamic IPA reaction, the chemically bonded and molecularly resilient (regenerative) IEPM material incorporates significant fracture toughness, loss modulus (material damping), and reduced elastic modulus into structural substrates and high-tenacity fibers to which it is adhered. | 2022-07-07 |
20220213258 | THERMOPLASTIC POLYURETHANE FILM AND DENTAL APPLIANCES FORMED THEREFROM - A method includes reactively extruding a polymeric composition to form a film. The polymeric composition includes a polyisocyanate and at least one dimer fatty diol. | 2022-07-07 |
20220213259 | Curing agent composition for an epoxy resin compound, epoxy resin compound and multi-component epoxy resin system with improved low-temperature curing - A curing agent composition can be used for a multi-component epoxy resin compound for the chemical fastening of construction elements. An epoxy resin compound and a multi-component epoxy resin system are useful. A method can be used for the chemical fastening of construction elements in boreholes. A combination of a salt (S) with a phenol derivative can be used for the chemical fastening of construction elements, in particular at low temperatures (≤0° C.), to improve the curing and the pull-out strength. | 2022-07-07 |
20220213260 | PHOTOACTIVE MACROMOLECULES AND USES THEREOF - The present invention provides water soluble photoactive macromolecular complexes and methods for detecting an analyte in a sample by using a binding agent conjugated to a water soluble photoactive macromolecule. | 2022-07-07 |
20220213261 | Fabrics with Interpenetrating Polymer Networks of Breathable Elastomeric Composites for Nanoscale Diffusion Control and Protection - An interpenetrating network (IPN) polymer membrane material includes a soft polyurethane interspersed with a crosslinked conducting polymer. The material can be reversibly “switched” between its oxidized and reduced states by the application of a small voltage, ˜1 to 4 volts, thus modulating its diffusivity. | 2022-07-07 |
20220213262 | Modulating Fabric Diffusivity Using Tether-Containing Conducting Polymers - An interpenetrating network (IPN) polymer membrane material includes a soft polyurethane interspersed with a crosslinked conducting polymer. The material can be reversibly “switched” between its oxidized and reduced states by the application of a small voltage, ˜1 to 4 volts, thus modulating its diffusivity. | 2022-07-07 |
20220213263 | RECYCLABLE MOLDED ARTICLES FROM BLENDS OF COPOLYESTERS AND RECYCLED PET - The present disclosure relates to recyclable molded articles made from blends of recycled PET and copolyester compositions which comprise residues of terephthalic acid, neopentyl glycol (NPG), 1,4-cyclohexanedimethanol (CHDM), ethylene glycol (EG), and/or 2,2,4,4-tetramethyl-1,3-cyclobutanediol residues, in certain compositional ranges that are thick-walled (>4 mm), have a high level of recycled PET content, have low haze and are recyclable in a PET stream. | 2022-07-07 |
20220213264 | POLYESTERS FROM LIGNIN-BASED MONOMERS - The invention is directed to polyesters comprising the following repeating unit of formula (I) wherein: R | 2022-07-07 |
20220213265 | ARGININE-BASED ANTIBACTERIAL POLYMERS WITH UCST PROPERTY - The present invention concerns a polymer comprising repetitive units having the following formula (I) wherein R | 2022-07-07 |
20220213266 | Blends that consist of TPU and polyamide - A composition contains at least a thermoplastic polyurethane (TPU-1) and a copolyamide (PA-1), prepared by polymerization of at least one lactam and of a monomer mixture (M). The monomer mixture (M) contains at least a C | 2022-07-07 |
20220213267 | EXTREME HIGH TEMPERATURE STABLE ADHESIVES AND COATINGS - The present invention provides curable polyimides with low color that are resistant to long term thermo-oxidative degradation. These materials, which include polyimides that are fully aromatic, are synthesized in anisole and are contemplated for use in high temperature applications such as in the aerospace industry and for use as encapsulants for light emitting diodes that will be exposed to high temperatures. | 2022-07-07 |
20220213268 | DUAL-CURE METHOD AND SYSTEM FOR FABRICATION OF 3D POLYMERIC STRUCTURES CROSS-REFERENCE TO EARLIER APPLICATIONS - A dual-cure method for forming a solid polymeric structure is provided. An end-capped, imide-terminated prepolymer is combined with at least one photopolymerisable olefinic monomer, at least one photoinitiator, and a diamine, to form a curable resin composition, which, in a first step, is irradiated under conditions effective to polymerize the at least one olefinic monomer, thus forming a scaffold composed of the prepolymer and the polyolefin with the diamine trapped therein. The irradiated composition is then thermally treated at a temperature effective to cause a transimidization reaction to occur between the prepolymer and the diamine, thereby releasing the end caps of the prepolymer and providing the solid polymeric structure. A curable resin composition comprising an end-capped, imide-terminated prepolymer, at least one photopolymerisable olefinic monomer, at least one photoinitiator, and a diamine, is also provided, as are related methods of use. | 2022-07-07 |